Bicycle Therapeutics (BCYC) Q3 2026 earnings summary

Executive summary

• Q3 2026 net loss narrowed to $10.5M from $59.1M YoY, reflecting lower operating costs and $34.1M recognized upon Bayer’s collaboration termination.

• March reprioritization focuses resources on nuzefatide pevedotin and next-generation conjugates; planned actions are expected to reduce annual operating expenses by ~50%.

Financial highlights

• Q3 collaboration revenue was $34.1M vs. $11.7M YoY; 9M revenue was $35.6M vs. $24.6M, with Bayer termination-related recognition driving the increase.

• Q3 operating expenses fell to $47.5M from $77.3M YoY; 9M expenses fell to $169.1M from $247.0M, reflecting lower R&D and G&A spending.

• Q3 net loss was $10.5M vs. $59.1M; 9M net loss was $121.6M vs. $198.8M.

• 9M operating cash use was $155.8M vs. $230.3M; cash, cash equivalents and restricted cash totaled $470.0M at September 30, 2026.

Outlook and guidance

• Cash and cash equivalents of $469.9M are expected to fund operating expenses and capital expenditures for at least 12 months from filing; other Q3 materials project runway into 2030.

• Expenses are expected to decrease near term from cost savings and reprioritization, but may rise with continued clinical development, pipeline expansion and potential commercialization preparation.

• Collaboration revenue is expected to decline near term after Bayer’s September 2026 termination; future revenue may vary with service activity, milestones, options and partner payments.

• Further nuzefatide updates and Duravelo-2 survival data are expected in 2027; the BT1702 company-sponsored clinical trial is expected to begin in 2H 2027.